IPSEN PHARMA

Company Overview

Ipsen Pharma is a France-based pharmaceutical company founded in 1929 and engaged in developing pharmaceutical products that target oncology, endocrinology, hematology, and neuromuscular disorders.

The company’s products include Decapeptyl (a peptide formulation for injection in the treatment of advanced prostate cancer), Hexvix (to enhance detection of bladder cancer) and Somatuline/Somatuline Autogel (used in the treatment of acromegaly and neuroendocrine tumors). Ipsen also offers NutropinAq (liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults.), Increlex (for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency) and Dysport (to treat spasticity of upper limbs following a stroke and the spasticity of other muscles). It also provides Smecta, Forlax and Tanakan. The company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; Adenuric for the treatment of gout; and Exforge, which is used in the treatment of hypertension. It is also developing products in the areas of neurology, endocrinology and uro-oncology.

The group additionally markets primary care products to treat gastroenterology, cardiovascular and cognitive conditions. Ipsen operates major research and development centers in Paris, France; Boston, Mass.; and London, U.K., which churn out products to the global therapeutic market. Its R&D efforts focus on peptide engineering, protein engineering, medicinal chemistry, and advanced drug delivery. The company markets its products directly, as well as through third-party distributors in nearly 100 countries. It has also formed strategic development and marketing alliances with Roche and Novartis.

Financial Highlights (FY 2024)

Company's Business Segments

• Healthcare Solutions : The company develop and commercialize advanced medicines for oncology, rare diseases, and neuroscience.